Home » Stocks » Vericel

Vericel Corporation (VCEL)

Stock Price: $20.12 USD -0.22 (-1.08%)
Updated Oct 27, 2020 12:32 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 910.44M
Revenue (ttm) 116.58M
Net Income (ttm) -3,000
Shares Out 45.25M
EPS (ttm) 0.00
PE Ratio n/a
Forward PE 38.91
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $20.12
Previous Close $20.34
Change ($) -0.22
Change (%) -1.08%
Day's Open 20.36
Day's Range 20.12 - 20.98
Day's Volume 100,777
52-Week Range 6.78 - 22.26

More Stats

Market Cap 910.44M
Enterprise Value 856.01M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 45.25M
Float 44.69M
EPS (basic) 0.02
EPS (diluted) 0.00
FCF / Share 0.22
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 1.11%
Payout Ratio n/a
Shares Short 4.36M
Short Ratio 7.32
Short % of Float 9.76%
Beta 2.72
PE Ratio n/a
Forward PE 38.91
P/FCF Ratio 89.88
PS Ratio 7.81
PB Ratio 8.50
Revenue 116.58M
Operating Income -1.13M
Net Income -3,000
Free Cash Flow 10.13M
Net Cash 54.43M
Net Cash / Share 1.20
Gross Margin 68.86%
Operating Margin -0.97%
Profit Margin n/a
FCF Margin 8.69%
ROA -0.52%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 6
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$27.71*
(37.72% upside)
Low
24.0
Current: $20.12
High
32.0
Target: 27.71
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue11890.8663.9254.3851.1728.800.020.020.020.09
Revenue Growth29.71%42.13%17.54%6.28%77.69%151457.89%-9.52%16.67%-79.78%-
Gross Profit80.2858.7033.5726.0824.7011.500.020.020.010.06
Operating Income-11.25-3.91-14.98-19.25-16.67-23.53-20.96-33.76-29.04-17.80
Net Income-9.67-8.14-17.29-19.57-16.34-19.92-15.62-29.47-19.67-14.56
Shares Outstanding44.1840.2433.3623.0923.7611.643.022.061.931.24
Earnings Per Share-0.22-0.20-0.52-1.18-0.97-2.23-6.95-16.25-10.18-11.80
Operating Cash Flow-7.18-0.41-13.18-19.89-13.35-25.41-19.94-29.55-24.49-15.09
Capital Expenditures-2.62-2.68-1.51-1.42-2.43-0.83-0.04-0.27-1.03-0.12
Free Cash Flow-9.80-3.09-14.69-21.31-15.77-26.24-19.98-29.82-25.52-15.21
Cash & Equivalents69.8182.9226.8622.9814.5830.348.0613.645.5319.12
Total Debt27.70-17.2410.130.070.11-0.040.080.31
Net Cash / Debt42.1082.929.6212.8514.5130.238.0613.605.4518.81
Assets15311954.5848.6034.3147.589.2215.187.7420.53
Liabilities42.1516.4632.0423.8912.1811.945.325.6720.715.75
Book Value11110222.5424.7122.1335.643.89-32.10-12.9714.78
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Vericel Corporation
Country United States
Employees 241
CEO Dominick C. Colangelo

Stock Information

Ticker Symbol VCEL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VCEL
IPO Date February 4, 1997

Description

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. It markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to dilated cardiomyopathy. In addition, its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for debridement of severe thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.